The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Real or fake? Tempted to say not true but you never know...
https://twitter.com/vanadiumhighs/status/1245980201680584704?s=21
Make your mind up Icartz thought it was 5p an hour ago?
Press release
Synairgen plc
('Synairgen' or the 'Company')
Synairgen confirms commencement of dosing in trial of SNG001 in COVID-19
Southampton, UK - 31 March 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that it has now commenced dosing patients in its trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients. This announcement follows the one made by the Company on 18 March 2020.
The first patient has been dosed at the initial trial site (University Hospital Southampton NHS Foundation Trust). Synairgen has initiated a further six trial sites which are expected to start dosing in the coming days.
Richard Marsden, CEO of Synairgen, commented: "We are delighted to get this trial underway with the dosing of the first patient. The team has worked tirelessly and intensively with the relevant authorities and collaborators to get to this stage, and we now look forward to recruiting more patients and completing the trial as soon as possible. A successful outcome from this trial in COVID-19 patients would be a very important step towards a major breakthrough in the fight against this coronavirus pandemic."